Tharimmune (NASDAQ:THAR – Get Free Report) posted its earnings results on Tuesday. The company reported ($2.02) earnings per share (EPS) for the quarter, Zacks reports.
Tharimmune Trading Down 2.1 %
Shares of Tharimmune stock traded down $0.03 during trading hours on Thursday, reaching $1.41. 4,380 shares of the company’s stock were exchanged, compared to its average volume of 64,450. Tharimmune has a 52-week low of $1.28 and a 52-week high of $7.46. The company has a fifty day moving average of $1.75 and a 200-day moving average of $2.12.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on THAR. Rodman & Renshaw assumed coverage on Tharimmune in a report on Friday, December 6th. They issued a “buy” rating and a $17.00 price target for the company. RODMAN&RENSHAW raised shares of Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th.
About Tharimmune
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
Read More
- Five stocks we like better than Tharimmune
- Investing in Construction Stocks
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- What is the Hang Seng index?
- Top 3 Beverage Stocks Pouring Out Profits
- Best Stocks Under $5.00
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
